Last quarter (Q ), Protect Pharmaceutical's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Protect Pharmaceutical's net income was $-4.43K. See Protect Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 17	Dec 16	Dec 15	Dec 14	Dec 13
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	$ 0.00	$ 0.00
Gross Profit	-	-	-	-	$ 0.00	$ 0.00
Operating Expense	$ 707.00	$ 115.40K	$ 41.71K	$ 30.03K	$ 30.85K	$ 23.94K
Operating Income	$ -707.00	$ -115.40K	$ -41.71K	$ -30.03K	$ -30.85K	$ -23.94K
Net Non Operating Interest Income Expense	$ -14.33K	$ -7.21K	$ 0.00	-	-	-
Other Income Expense	-	-	-	$ -605.44K	$ 488.99K	-
Pretax Income	$ -15.04K	$ -122.61K	$ -41.71K	$ -635.46K	$ 458.14K	$ -23.94K
Tax Provision	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -15.04K	$ -122.61K	$ -41.71K	$ -635.46K	$ 458.14K	$ -23.94K
Basic EPS	$ >-0.01	$ -0.11	$ -0.04	$ -1.44	$ 8.48	$ 0.00
Diluted EPS	$ >-0.01	$ -0.11	$ -0.04	$ -1.44	$ 8.48	$ 0.00
Basic Average Shares	$ 4.45M	$ 1.11M	$ 1.11M	$ 442.17K	$ 54.05K	$ 44.57K
Diluted Average Shares	$ 5.31M	$ 1.20M	$ 1.11M	$ 442.17K	$ 89.46K	$ 44.57K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 707.00	$ 115.40K	$ 41.71K	$ 30.03K	$ 30.85K	$ 23.94K
Net Income From Continuing And Discontinued Operation	$ -15.04K	$ -122.61K	$ -41.71K	$ -635.46K	$ 458.14K	$ -23.94K
Normalized Income	$ -15.04K	$ -122.61K	$ -41.71K	$ -30.03K	$ -30.85K	$ -23.94K
Interest Expense	$ 14.33K	$ 7.21K	$ 0.00	-	-	-
EBIT	$ -707.00	$ -115.40K	$ -41.71K	$ -30.03K	$ -30.85K	$ -23.94K
EBITDA	$ -707.00	$ -115.40K	$ -41.71K	$ -30.03K	$ -30.85K	$ -23.94K

Currency in USD

Protect Pharmaceutical Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing